Peking prognostic score is a useful prognostic factor in patients with gastric cancer liver metastases receiving hepatectomy

Jianping Xiong, Yunzi Wu, Haitao Hu, Wenzhe Kang, Yang Li, Peng Jin, Xinxin Shao, Weikun Li, Yibin Xie* and Yantao Tian*

Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Background: The present work evaluated how Peking prognostic score (PPS), the new prognostic index determined according to sarcopenia and lymphocyte-to-C-reactive protein ratio (LCR), was a prognostic factor for patients with gastric cancer liver metastases (GCLM) who received hepatectomy.

Methods: This work extracted information about patients with GCLM who underwent hepatectomy from June 2012 to May 2018. The PPS of the patients was calculated from sarcopenia status and LCR before surgery, and patients were then divided into three groups based on their PPS. This work also carried out univariate and multivariate analyses for identifying variables that were linked with overall survival (OS) together with recurrence-free survival (RFS) after hepatectomy among three groups according to PPS.

Results: This work included 108 GCLM cases who received hepatectomy. All cases were classified into 3 groups, i.e., 26 (24.1%), 48 (44.4%), and 34 (31.5%) in groups 0–2, respectively. PPS exhibited positive relation with age (p < 0.001), body mass index (BMI; p = 0.012), and liver metastasis number. The relapse rate after hepatectomy in patients with GCLM was 69.4%. Additionally, the remnant liver relapse rates of groups 0–2 were 80.0, 68.7, and 53.5%. Patients in group 0 had significantly increased remnant liver relapse rates when compared with those in groups 0 and 1. PPS was significantly related to relapse patterns (p = 0.003). Relative to group 0, those of the other 2 groups showed dismal OS [hazard ratio (HR) = 3.98, 7.49 for groups 1 and 2; p < 0.001] along with RFS (HR = 3.65, 5.33 for groups 1 and 2; p < 0.001). As revealed by multivariate analysis, PPS independently predicted OS (p < 0.001) together with RFS (p < 0.001).
Conclusion: The PPS could be an easy nutrition-inflammation prognostic scoring system and an independent preoperative predictor of survival for GCLM cases after hepatectomy.

KEYWORDS

gastric cancer, liver metastases, hepatectomy, Peking prognostic score, prognostic scoring system

Introduction

Gastric cancer (GC) accounts for the 5th cancer in terms of its incidence, which affects 1,033,701 people every year. Additionally, GC accounts for the 3rd place among the frequent factors leading to cancer-related death, and 782,685 death cases are reported annually (1). Despite the numerous efforts conducted on GC diagnosis and treatment, its survival decreases due to distant metastases (DM). The liver represents a frequent organ subject to DM of GC, with the GC liver metastasis (GCLM) rate of 9.9ñ18.7% (2, 3). For GCLM cases, they have a median survival of approximately 7ñ12 months (4). Long-term survival can hardly be achieved among GCLM cases, although first-line chemotherapy is applied (4). As palliative chemotherapy has poor overall survival (OS) outcomes, hepatectomy is widely analyzed to be the appropriate way for improving patient survival. Numerous articles suggest that hepatectomy is advantageous for GCLM in the last 20 years (5ñ7). Some recent large articles suggest that for GCLM receiving hepatectomy, the 5-year OS was 31.1ñ39.5%(8, 9). However, hepatectomy is associated with a high relapse rate; therefore, determining hepatectomy timing and indications for GCLM cases is not easy. Consequently, it is essential to develop approaches to assess the hepatectomy feasibility in GCLM cases.

In recent years, inflammatory, immune, and nutritional statuses, which are the host-associated factors, receive wide attention in the prediction of postoperative outcomes within diverse cancer types. Typically, platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and C-reactive protein ratio-albumin ratio (CAR) along with neutrophil-to-lymphocyte ratio (NLR) have been identified as factors predicting the prognosis of cancers. As reported recently, low lymphocyte-to-C-reactive protein ratio (LCR) independently predicted OS and recurrence-free survival (RFS) among GC cases who underwent gastrectomy (10, 11). In addition, LCR showed the greatest sensitivity to predict survival when compared with other inflammation-related scores (11). Sarcopenia, one of the age-related muscle mass, strength, and functional losses, is becoming a severe medical problem among the aging societies (12). It can be usually detected in GC cases, and its incidence is more than 6.8ñ57.7% among patients with GC (13). Additionally, it shows significant relation with the poor long-term prognosis among patients with GC receiving surgery (14). Our previous work indicated that sarcopenia effectively predicted prognosis of recurrence in patients with GCLM receiving hepatectomy (15). The Peking prognostic score (PPS), first proposed by Xiong et al., consists of sarcopenia and LCR and shows high relation to GC prognosis (16). Additionally, it exhibits increased accuracy when compared with additional prognostic factors for the prediction of survival (16). Nonetheless, the association of PPS with long-run patients with GCLM survival after hepatectomy for GCLM is still unclear.

This article assessed whether PPS preoperatively affected the long-run survival of GCLM after hepatectomy.

Materials and methods

This article obtained approval from the Ethics Committee of the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (NCC2020C-220). Each experiment was carried out following Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis and Declaration of Helsinki.

Research design and objects

This study assessed patients with GCLM who underwent hepatectomy in the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College during June 2012ñMay 2018. This work set patient exclusion criteria below (1) those with an unresectable extrahepatic lesion (n = 15), (2) those who received several hepatectomies due to liver metastatic relapse (n = 4), (3) patients who underwent R1/R2 resection (n = 6), (4) patients having inadequate or inaccurate medical records (n = 5), (5) preoperative computed tomography (CT) scans missing (n = 12), and (6) those who were dying due to complications after surgery (n = 6). Finally, 108 cases were enrolled in the cohort (Figure 1). In this study, resected liver segment number ≥ 3 was deemed as major hepatectomy, while that < 3
as a minor hepatectomy (17). Recurrences were categorized as remnant liver and extrahepatic sites. Extrahepatic site recurrence included local (primary site), lymph node, lung, bone/brain, and peritoneal dissemination recurrence. Follow-up after surgery was carried out every 3 months within the first 2 years, whereas every half a year thereafter. This study deemed the primary end point OS as the period between surgery and all-cause mortality or final follow-up, whereas the secondary end point RFS was the period between surgery and mortality or disease relapse.

**Peking prognostic score and other prognostic scoring systems**

Muscle quality was assessed ahead of time for identifying sarcopenia cases. CT was also employed for the accurate assessment of muscle mass. Additionally, the CT-based sarcopenia thresholds for gender-specific skeletal muscle index (SMI) of the third lumbar vertebra (L3) were ≤ 40.8, 34.9 cm²/m² for men and women, separately, as proposed by Zhuang for Chinese GC population (18). The PPS model consisted of two parameters, namely, LCR and sarcopenia status. According to Xiong et al’s method, the scores were 0, 1, 2, and 3 for cases with LCR > 6,000 without sarcopenia, LCR > 6,000 with sarcopenia, LCR ≤ 6,000 without sarcopenia, and LCR ≤ 6,000 with sarcopenia, separately. All cases were classified into three groups based on their PPS scores: cases with the scores of 0, 1/2, and 3 were classified as groups 0–2, separately (Table 1).

**Statistical methods**

Kaplan–Meier (KM) survival analysis was conducted, whereas the log-rank test was employed in the analysis. This work also conducted univariate and multivariate analyses by Cox proportional hazards regression model. All of those prognostic factors identified by univariate analysis upon p < 0.1 were incorporated into multivariate regression. p < 0.05 represented statistical significance. R software version 4.0.2 (R Foundation for Statistical Computing, Vienna, Austria) together with JMP statistical software package (SAS Institute, Inc., Cary, NC, United States) was adopted in statistical analysis.

**Results**

**Patient features**

This work included altogether 108 GCLM cases who received hepatectomy, among them, 84 (77.6%) were men and...
TABLE 1. The definition of the Peking prognostic score.

| Scoring system                        | Score | Group       |
|----------------------------------------|-------|-------------|
| The PPS                                |       |             |
| Sarcopenia (No) and LCR (≥ 6,000)      | 0     | 0           |
| Sarcopenia (Yes) and LCR (≥ 6,000)     | 1     | 1           |
| Sarcopenia (No) and LCR (≤ 6,000)      | 2     | 1           |
| Sarcopenia (Yes) and LCR (≤ 6,000)     | 3     | 2           |

LCR, lymphocyte-to-C-reactive protein ratio.

24 (22.4%) were women (Table 2). The age at hepatectomy ranged from 57.9 to 73.6 (mean, 63.5) years. With regard to liver metastasis, 41 cases (38.0%) developed synchronous metastatic lesions, whereas 67 cases (62.0%) developed metachronous metastatic lesions (Table 2). In total, 72 cases (66.7%) developed solitary liver metastatic lesions, whereas 36 (33.3%) developed multiple liver metastatic lesions (Table 2). In total, 60 cases (55.7%) underwent neoadjuvant chemotherapy (NACT), whereas 73 (67.5%) underwent adjuvant chemotherapy (ACT) (Table 2). Patients were divided into 3 groups, i.e., 26 (24.1%), 48 (44.4%), and 34 (31.5%) in groups 0 (PPS = 0), 1 (PPS = 1/2), and 2 (PPS = 3), separately (Table 2). With regard to OS rates, they were 78.6, 45.8, and 33.4%, separately in GCLM cases who received hepatectomy, while their RFS rates at 1, 3, and 5 years were 51.7, 36.5, and 27.3%, separately.

**Associations of Peking prognostic score with clinicopathological characteristics**

Table 2 presents the relation between PPS and patient clinicopathological characteristics. PPS was significantly related to advanced age (≥ 65.0 years; p < 0.001) together with decreased body mass index (BMI; < 18.5 kg/m²; p = 0.012). Additionally, PPS showed a significant relationship with liver metastasis number (p = 0.002). The relapse rate after hepatectomy in patients with GCLM was 69.4%. Additionally, the remnant liver relapse rates of groups 0–2 were 80.0, 68.7, and 53.5%. Patients in group 0 had significantly increased remnant liver relapse rates when compared with those in groups 0 and 1. PPS was significantly related to relapse patterns (p = 0.003; Table 3).

**Clinical role of preoperative Peking prognostic score in patients with gastric cancer liver metastases**

As revealed by KM survival analysis, OS and RFS were evidently reduced as the PPS group increased step-wise (OS, RFS: log-rank test, p < 0.001; Figures 2A,B). In comparison with group 0, those of groups 1/2 showed decreased OS and RFS. Upon multivariate regression, PPS independently predicted OS (HR = 2.12, 95% CI = 1.14–4.25, p < 0.001; HR = 4.76, 95% CI = 1.49–6.90, p < 0.001 for PPS groups 1 and 2 separately) and RFS (HR = 3.08, 95% CI = 1.29–4.38, p < 0.001; HR = 4.32, 95% CI = 1.75–6.87, p < 0.001 for PPS groups 1 and 2 separately; Tables 4, 5).

Factors significantly related to OS upon univariate analysis were BMI (p < 0.001), serum albumin (p < 0.001), carcinoembryonic antigen (CEA) levels (p < 0.001), ACT (p = 0.030), liver metastasis number (p < 0.001), and maximal liver metastasis size (p < 0.001; Table 4). Multivariate analysis identified serum albumin (HR = 1.69; 95% CI = 1.24–2.76; p = 0.002), liver metastasis number (HR = 1.75; 95% CI = 1.29–2.93; p < 0.01), and maximal liver metastasis size (HR = 1.89; 95% CI = 1.13–3.28; p = 0.008) to be independent factors predicting OS (Table 4).

Factors significantly related to RFS upon univariate analysis were serum albumin (p < 0.001), liver metastasis number (p < 0.001), and maximal liver metastasis diameter (p = 0.002; Table 5). Multivariate analysis identified liver metastasis number (HR = 1.82; 95% CI = 1.16–2.70; p < 0.001) and maximal liver metastasis size (HR = 1.43; 95% CI = 1.08–3.05, p = 0.004) to be independent factors predicting RFS (Table 5).

**Discussion**

This article analyzed whether PPS was of prognostic value in GCLM cases receiving hepatectomy and identified PPS as the factor independently predicting long-term survival of GCLM cases. According to this work, PPS was potently linked to old age (≥ 65.0 years) and declined BMI (< 18.5 kg/m²) together with liver metastasis number (> 1).

Liver metastasis may take place within around 5–14% of cases receiving GC surgery (2). Liver metastasis treatment plays a critical role in improving the prognosis of GC cases. GCLM cases can be traditionally treated by palliative chemotherapy (19). However, numerous articles suggest that liver metastatic resection can significantly improve some patient survival in the last several years. As reported in Far Eastern Research, GCLM survival was posthepatectomy increased when compared with Western studies (2). According to the Chinese consensus on the diagnosis and treatment of GC with liver metastases, type I patients can choose surgical treatments (3). The criteria are as follows: (1) gastric tumors: depth of invasion ≤ T4a; lymph node metastases within D2 lymph node dissection (not including Bulky N2). (2) Bulky N2: at least one node of ≥ 3 cm in diameter or at least three consecutive nodes
### TABLE 2 Association of PPS and clinicopathological characteristics in patients with GCLM after hepatectomy.

| Clinicopathological features | All cases \((n = 108)\) | Group 0 \((n = 26)\) | Group 1 \((n = 48)\) | Group 2 \((n = 34)\) | \(P\)-value |
|-----------------------------|------------------------|---------------------|---------------------|---------------------|------------|
| Age \(\geq 65.0\) | 63 (58.7) | 7 (26.9) | 28 (58.3) | 28 (82.3) | \(P < 0.001\) |
| Age \(< 65.0\) | 45 (41.3) | 19 (73.1) | 20 (41.7) | 6 (17.7) | \(0.769\) |
| Gender | 84 (77.6) | 19 (73.1) | 38 (79.1) | 27 (79.4) | \(0.012\) |
| Male | 24 (22.4) | 7 (26.9) | 10 (20.9) | 7 (20.6) | \(0.012\) |
| Female | 60 (55.2) | 12 (46.2) | 18 (37.5) | 20 (58.8) | \(0.091\) |
| BMI (kg/m2) \(< 18.5\) | 16 (14.8) | 2 (7.7) | 6 (12.5) | 8 (23.5) | \(0.012\) |
| BMI (kg/m2) \(\geq 18.5\) | 92 (85.2) | 24 (92.3) | 42 (87.5) | 26 (76.5) | \(0.012\) |
| Serum albumin (g/dL) \(\geq 3.5\) | 83 (76.8) | 42 (72.4) | 42 (72.4) | 44 (78.6) | \(0.091\) |
| Serum albumin (g/dL) \(< 3.5\) | 25 (23.2) | 5 (19.2) | 11 (22.9) | 9 (26.5) | \(0.091\) |
| CEA (ng/mL) \(\geq 5.0\) | 61 (56.5) | 15 (57.6) | 26 (54.2) | 20 (58.8) | \(0.540\) |
| CEA (ng/mL) \(< 5.0\) | 47 (43.5) | 11 (42.4) | 22 (45.8) | 14 (51.2) | \(0.540\) |
| Tumor location of GC | 34 (31.4) | 9 (34.6) | 14 (29.2) | 11 (32.3) | \(0.601\) |
| Upper | 74 (68.6) | 17 (65.4) | 34 (70.8) | 23 (67.7) | \(0.601\) |
| Middle/Lower | 54 (50.0) | 12 (46.1) | 25 (52.0) | 17 (50.0) | \(0.553\) |
| Lauren Classification | 33 (30.5) | 9 (34.6) | 14 (29.2) | 10 (29.4) | \(0.553\) |
| Diffused-type | 21 (19.5) | 5 (19.3) | 9 (18.8) | 7 (20.6) | \(0.553\) |
| Mixed | 54 (49.5) | 12 (46.1) | 25 (52.0) | 17 (50.0) | \(0.553\) |
| Timing of liver metastases | 67 (62.0) | 17 (65.3) | 29 (60.4) | 21 (61.7) | \(0.308\) |
| metachronous | 41 (38.0) | 9 (34.7) | 19 (39.6) | 13 (38.3) | \(0.308\) |
| synchronous | 56 (52.0) | 10 (40.0) | 17 (39.6) | 10 (29.4) | \(0.308\) |
| Number of liver metastases \(\leq 1\) | 72 (67.7) | 14 (53.8) | 31 (64.6) | 27 (79.4) | \(0.002\) |
| \(> 1\) | 36 (33.3) | 12 (46.2) | 17 (35.4) | 7 (20.6) | \(0.002\) |
| Maximum tumor size of the liver metastasis \(< 3\) | 68 (62.9) | 17 (65.3) | 28 (58.3) | 24 (70.6) | \(0.304\) |
| \(\geq 3\) | 40 (37.1) | 9 (34.7) | 20 (41.7) | 10 (29.4) | \(0.304\) |
| Type of hepatectomy | 86 (79.6) | 20 (80.8) | 40 (83.3) | 25 (76.4) | \(0.513\) |
| Minim | 22 (20.4) | 6 (23.1) | 8 (16.7) | 9 (23.6) | \(0.513\) |
| Major | 64 (59.5) | 14 (53.8) | 22 (43.2) | 21 (61.7) | \(0.513\) |
| Neoadjuvant chemotherapy | 48 (43.3) | 12 (46.1) | 20 (41.7) | 17 (50.0) | \(0.446\) |
| No | 60 (55.7) | 15 (57.7) | 28 (58.3) | 17 (50.0) | \(0.446\) |
| Yes | 35 (32.5) | 9 (34.6) | 18 (37.5) | 10 (29.5) | \(0.217\) |
| Adjuvant chemotherapy | 73 (67.5) | 18 (69.2) | 30 (62.5) | 24 (70.5) | \(0.217\) |
| Yes (Systemic chemotherapy/HAI/C/ Systemic chemotherapy + HAI/C) | 57 (52.3) | 14 (53.8) | 23 (47.9) | 20 (58.8) | \(0.217\) |

PPS, Peking prognostic score; GCLM, Gastric Cancer Liver Metastasis; BMI, body mass index; GC, gastric cancer; HAI/C, hepatic artery infusion chemotherapy.

### TABLE 3 Impact of PPS on the recurrence in patients with GCLM receiving hepatectomy.

| Patterns of recurrence | All cases \((n = 75)\) | Group 0 \((n = 15)\) | Group 1 \((n = 32)\) | Group 2 \((n = 28)\) | \(P\)-value |
|------------------------|------------------------|---------------------|---------------------|---------------------|------------|
| Remnant liver | 49 (65.3) | 12 (80.0) | 22 (68.7) | 15 (53.5) | \(P = 0.003\) |
| Extrahepatic sites (Lung/Lymph node/Peritoneal dissemination/Local (primary site)\(\)Bone/brain) | 26 (34.7) | 3 (20.0) | 10 (31.3) | 13 (46.5) | \(P = 0.003\) |

PPS, Peking prognostic score; GCLM, Gastric Cancer Liver Metastasis.
each of diameter ≥ 1.5 cm, along the coeliac, splenic, common, or proper hepatic arteries. Liver metastases: 1–3; maximal diameter ≤ 4 cm or limited to one liver lobe without involving important vessels or bile ducts. (3) Assessment of resectability: technological resectability of liver metastases judged by a hepatobiliary surgeon; meets the resection standard of hepatic reservation function assessment (3). Nevertheless, 5-year OS following hepatectomy was 27.7–42.3%, while the relapse rates after hepatectomy were 60–75% (9, 20, 21). Consequently, predicting and assessing relapse has been considered among GCLM cases receiving hepatectomy.

According to the results of recent studies, many favorable prognostic factors have been suggested, such as primary cancer (lower T and N stage, no lympho-vascular or serosal invasion), burden of hepatic disease (≤ 3 metastases, unilobar involvement, greatest lesion < 5 cm, and negative resection margins), and lower CEA and CA19.9 levels (9, 20, 21). An increasing number of articles have analyzed the relationship between malnutrition or systemic inflammation and tumor genesis, progression, and metastasis, which has been verified in different cancers that include GC, resulting in looking for markers related to nutrition and inflammation and developing the new prognosis scoring system. Serum CRP has been the typical marker reflecting systemic inflammatory responses, in addition, an increased CRP level related to poor prognosis for GC. According to Okugawa and Nakamura, LCR served as the prognostic biomarker for GC (10, 11), resectable colorectal cancer (CRC) (22), and unresectable metastatic CRC (23). Moreover, LCR is recently suggested to show the highest accuracy in predicting survival when compared with inflammatory scores, such as NLR, CAR, LMR, or PLR (11, 22, 23). Sarcopenia, the skeletal muscle mass, and functional loss are poor nutritional status. Further, it is also identified to be a marker for tumor cachexia. In the last 10 years, sarcopenia’s clinical significance for cancer patients has aroused wide attention, such as GC. Yu et al. investigated how sarcopenia plus fibrinogen-albumin ratio (FAR) affected intrahepatic cholangiocarcinoma cases postoperatively (24). The results showed that cases showing both sarcopenia and increased FAR were associated with dismal prognostic outcomes relative to additional patients (24). In addition, sarcopenia plus hepatolithiasis potently predicted the dismal prognostic outcome of intrahepatic cholangiocarcinoma cases receiving curative resection, suggesting the feasibility of sarcopenia plus hepatolithiasis in predicting the prognosis of intrahepatic cholangiocarcinoma cases preoperatively. Another study showed that sarcopenia combined with monocyte-to-lymphocyte ratio was the potent factor predicting OS in breast cancer (BC) cases with lymph node positiveness following mastectomy (25). Sarcopenia together with an increased modified Glasgow prognostic score (mGPS) that contained CRP predicted dismal survival for patients developing locoregional Renal Cell Carcinoma (26). Sarcopenia plus, an increased NLR, predicted the poorer OS of patients with colorectal cancer, stage IV GC, and biliary tract cancer (27–29). PPS is determined according to sarcopenia and LCR and has been suggested as an effective approach to evaluate both the nutritional and inflammatory status of patients with GC (30). As proposed by Xiong et al., PPS was the most effective index for predicting long-term outcomes and recurrence rates for localized GC cases (31). Meanwhile, our study further found that the PPS was a useful factor to predict GCLM prognosis after hepatectomy. Overall, preoperative assessment of inflammation and muscle mass possibly assists in making treatment decision for oncologists, which contributes to identify patients who can gain the best beneficial effects from curative hepatectomy. In addition, it helps us to determine the patients who have a higher disease relapse risk and are considered to receive individualized therapy.
### TABLE 4 Univariate and multivariate analysis of clinicopathologic variables in relation to overall survival in patients with GCLM after hepatectomy.

| Clinicopathological features | Univariate analysis | P-value | Multivariate analysis | P-value |
|-----------------------------|---------------------|---------|-----------------------|---------|
| Age                         | Reference 1.42 (0.84, 3.76) | 0.311 | Reference 1.90 (0.87, 2.83) | 0.182 |
| < 65.0                      | Reference 3.13 (1.47, 4.22) | < 0.001 | Reference 1.90 (0.87, 2.83) | 0.182 |
| ≥ 65.0                      | Reference 2.15 (1.30, 3.96) | < 0.001 | Reference 1.69 (1.24, 2.76) | 0.002 |
| Gender                      | Reference 1.97 (1.24, 3.87) | < 0.001 | Reference 1.41 (1.17, 2.63) | 0.005 |
| BMI (kg/m2)                 | Reference 3.13 (1.47, 4.22) | < 0.001 | Reference 1.90 (0.87, 2.83) | 0.182 |
| ≥ 18.5                      | Reference 2.15 (1.30, 3.96) | < 0.001 | Reference 1.69 (1.24, 2.76) | 0.002 |
| < 18.5                      | Reference 1.97 (1.24, 3.87) | < 0.001 | Reference 1.41 (1.17, 2.63) | 0.005 |
| Serum albumin (g/dL)        | Reference 3.13 (1.47, 4.22) | < 0.001 | Reference 1.90 (0.87, 2.83) | 0.182 |
| ≥ 3.5                       | Reference 2.15 (1.30, 3.96) | < 0.001 | Reference 1.69 (1.24, 2.76) | 0.002 |
| < 3.5                       | Reference 1.97 (1.24, 3.87) | < 0.001 | Reference 1.41 (1.17, 2.63) | 0.005 |
| CEA (ng/mL)                 | Reference 3.13 (1.47, 4.22) | < 0.001 | Reference 1.90 (0.87, 2.83) | 0.182 |
| ≥ 5.0                       | Reference 2.15 (1.30, 3.96) | < 0.001 | Reference 1.69 (1.24, 2.76) | 0.002 |
| < 5.0                       | Reference 1.97 (1.24, 3.87) | < 0.001 | Reference 1.41 (1.17, 2.63) | 0.005 |
| Tumor location of GC        | Reference 3.13 (1.47, 4.22) | < 0.001 | Reference 1.90 (0.87, 2.83) | 0.182 |
| Upper                       | Reference 2.15 (1.30, 3.96) | < 0.001 | Reference 1.69 (1.24, 2.76) | 0.002 |
| Middle/Lower                | Reference 1.97 (1.24, 3.87) | < 0.001 | Reference 1.41 (1.17, 2.63) | 0.005 |
| Lauren Classification       | Reference 3.13 (1.47, 4.22) | < 0.001 | Reference 1.90 (0.87, 2.83) | 0.182 |
| Intestinal-type             | Reference 2.15 (1.30, 3.96) | < 0.001 | Reference 1.69 (1.24, 2.76) | 0.002 |
| Diffused-type               | Reference 1.97 (1.24, 3.87) | < 0.001 | Reference 1.41 (1.17, 2.63) | 0.005 |
| Mixed                       | Reference 3.13 (1.47, 4.22) | < 0.001 | Reference 1.90 (0.87, 2.83) | 0.182 |
| Timing of liver metastases | Reference 1.97 (1.24, 3.87) | < 0.001 | Reference 1.41 (1.17, 2.63) | 0.005 |
| synchronous                 | Reference 3.13 (1.47, 4.22) | < 0.001 | Reference 1.90 (0.87, 2.83) | 0.182 |
| metachronous                | Reference 1.97 (1.24, 3.87) | < 0.001 | Reference 1.41 (1.17, 2.63) | 0.005 |
| Number of liver metastases | Reference 3.13 (1.47, 4.22) | < 0.001 | Reference 1.90 (0.87, 2.83) | 0.182 |
| ≤ 1                         | Reference 2.15 (1.30, 3.96) | < 0.001 | Reference 1.69 (1.24, 2.76) | 0.002 |
| >1                          | Reference 1.97 (1.24, 3.87) | < 0.001 | Reference 1.41 (1.17, 2.63) | 0.005 |
| Maximum diameter of the liver metastasis | Reference 3.13 (1.47, 4.22) | < 0.001 | Reference 1.90 (0.87, 2.83) | 0.182 |
| < 3                         | Reference 2.15 (1.30, 3.96) | < 0.001 | Reference 1.69 (1.24, 2.76) | 0.002 |
| ≥ 3                         | Reference 1.97 (1.24, 3.87) | < 0.001 | Reference 1.41 (1.17, 2.63) | 0.005 |
| Type of hepatectomy         | Reference 3.13 (1.47, 4.22) | < 0.001 | Reference 1.90 (0.87, 2.83) | 0.182 |
| Minor                       | Reference 2.15 (1.30, 3.96) | < 0.001 | Reference 1.69 (1.24, 2.76) | 0.002 |
| Major                       | Reference 1.97 (1.24, 3.87) | < 0.001 | Reference 1.41 (1.17, 2.63) | 0.005 |
| Neoadjuvant chemotherapy    | Reference 3.13 (1.47, 4.22) | < 0.001 | Reference 1.90 (0.87, 2.83) | 0.182 |
| No                          | Reference 2.15 (1.30, 3.96) | < 0.001 | Reference 1.69 (1.24, 2.76) | 0.002 |
| Yes                         | Reference 1.97 (1.24, 3.87) | < 0.001 | Reference 1.41 (1.17, 2.63) | 0.005 |
| Adjuvant chemotherapy       | Reference 3.13 (1.47, 4.22) | < 0.001 | Reference 1.90 (0.87, 2.83) | 0.182 |
| No                          | Reference 2.15 (1.30, 3.96) | < 0.001 | Reference 1.69 (1.24, 2.76) | 0.002 |
| Yes (Systemic chemotherapy/HAIC/Systemic chemotherapy + HAIC) | Reference 1.97 (1.24, 3.87) | < 0.001 | Reference 1.41 (1.17, 2.63) | 0.005 |
| PPS, Peking prognostic score | Reference 3.13 (1.47, 4.22) | < 0.001 | Reference 1.90 (0.87, 2.83) | 0.182 |
| 0                           | Reference 2.15 (1.30, 3.96) | < 0.001 | Reference 1.69 (1.24, 2.76) | 0.002 |
| 1                           | Reference 1.97 (1.24, 3.87) | < 0.001 | Reference 1.41 (1.17, 2.63) | 0.005 |
| 2                           | Reference 3.13 (1.47, 4.22) | < 0.001 | Reference 1.90 (0.87, 2.83) | 0.182 |
| 3                           | Reference 2.15 (1.30, 3.96) | < 0.001 | Reference 1.69 (1.24, 2.76) | 0.002 |
| 4                           | Reference 1.97 (1.24, 3.87) | < 0.001 | Reference 1.41 (1.17, 2.63) | 0.005 |

PPS, Peking prognostic score; GC, gastric cancer; GCLM, gastric cancer liver metastasis; BMI, body mass index; HAIC, hepatic artery infusion chemotherapy.

The present work had certain limitations. Firstly, although this study could evaluate the prognostic impact of preoperative PPS in patients with GCLM, selection bias still existed in a retrospective study. Moreover, our unicentric study only enrolled a small sample size and could not establish a validation cohort to further validate the results; therefore, more large prospective studies are warranted. Secondly, we adopted the sarcopenia definition created by Zhuang et al., which deemed sarcopenia criteria for the Chinese GC population (18). The cut-off values for the L3-SMI for the diagnosis of sarcopenia were 34.9 and 40.8 cm²/m² in men and women. The generalizability of findings in this work was mainly restricted to the Western population since L3-SMI thresholds utilized in this study were specific to geographic regions.
TABLE 5 Univariate and multivariate analyses of clinicopathologic variables in relation to recurrence-free survival in patients with GCLM after hepatectomy.

| Clinicopathological features | Univariate analysis | P-value | Multivariate analysis | P-value |
|-----------------------------|---------------------|---------|-----------------------|---------|
| Age                         | Reference 1.75 (0.79, 3.81) | 0.462 | Reference 1.87 (0.75, 2.66) | 0.340 |
| < 65.0                      |                      |         |                       |         |
| ≥ 65.0                      |                      |         |                       |         |
| Gender                      | Reference 0.80 (0.33, 3.11) | 0.337 |                       |         |
| Male                        |                      |         |                       |         |
| Female                      |                      |         |                       |         |
| BMI (kg/m2)                 | Reference 3.62 (1.60, 4.78) | < 0.001| Reference 1.90 (0.87, 3.01) | 0.214 |
| ≥ 18.5                      |                      |         |                       |         |
| < 18.5                      |                      |         |                       |         |
| Serum albumin (g/dL)        | Reference 2.89 (1.65, 4.52) | < 0.001| Reference 1.58 (1.23, 2.80) | 0.002 |
| ≥ 3.5                       |                      |         |                       |         |
| < 3.5                       |                      |         |                       |         |
| CEA (ng/mL)                 | Reference 2.14 (1.30, 3.95) | < 0.001| Reference 1.87 (0.72, 5.60) | 0.409 |
| ≥ 5.0                       |                      |         |                       |         |
| < 5.0                       |                      |         |                       |         |
| Tumor location of GC        | Reference 0.69 (0.58, 4.17) | 0.411 |                       |         |
| Upper                       |                      |         |                       |         |
| Middle/Lower                |                      |         |                       |         |
| Lauren Classification       | Reference 0.49 (0.40, 0.51) | 0.439 |                       |         |
| Intestinal-type             | 3.11 (0.69, 4.01) |         |                       |         |
| Diffused-type               | 1.87 (0.72, 5.60) |         |                       |         |
| Mixed                       |                      |         |                       |         |
| Timing of liver metastases  | Reference 1.55 (0.78, 4.12) | 0.442 |                       |         |
| metachronous synchronous    |                      |         |                       |         |
| Number of liver metastases | Reference 2.10 (1.28, 4.39) | < 0.001| Reference 1.82 (1.16, 2.70) | 0.001 |
| ≤ 1                         |                      |         |                       |         |
| >1                          |                      |         |                       |         |
| Maximum diameter of the liver metastasis | Reference 2.36 (1.36, 4.17) | < 0.001| Reference 1.43 (0.88, 2.05) | 0.274 |
| < 3                         |                      |         |                       |         |
| ≥ 3                         |                      |         |                       |         |
| Type of hepatectomy         | Reference 1.67 (0.70, 2.13) | 0.558 |                       |         |
| Minor                       |                      |         |                       |         |
| Major                       |                      |         |                       |         |
| Neoadjuvant chemotherapy    | Reference 0.75 (0.69, 1.74) | 0.116 |                       |         |
| No                          |                      |         |                       |         |
| Yes                         |                      |         |                       |         |
| Adjuvant chemotherapy       | Reference 0.78 (0.60, 1.96) | 0.330 |                       |         |
| No                          |                      |         |                       |         |
| Yes (Systemic chemotherapy/HAIC/Systemic chemotherapy + HAIC) | Reference 3.65 (1.80, 7.67) | < 0.001| Reference 3.08 (1.29, 4.38) | < 0.001|
| PPS                         |                      |         |                       |         |
| 0                           | 5.33 (2.10, 12.79) | < 0.001| Reference 4.32 (1.75, 6.87) | < 0.001|
| 1                           |                      |         |                       |         |
| 2                           |                      |         |                       |         |

PPS, Peking prognostic score; GC, gastric cancer; GCLM, gastric cancer liver metastasis; BMI, body mass index; HAIC, hepatic artery infusion chemotherapy.

Conclusion

In conclusion, PPS before surgery represents the simple and effective prognostic factor for patients with GCLM who underwent heptectomy. The PPS could utilize as a part of precisely predicting GCLM prognosis while improving treatment decision. With the prognostic model, oncologists can determine which cases can probably gain benefits from the aggressive surgery (hepatectomy), thus improving GCLM patient survival.
Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by Ethics Committee of National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

Author contributions

JX and YT conceived of the study and drafted the manuscript. YW, HH, WK, YL, and PJ were responsible for data collection. YW and JX were in charge of statistical analysis. YX, YT, XS, and WL helped to modify the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This present work was funded by the National Natural Science Foundation of China (81772642).

Acknowledgments

We thank the invaluable assistance from Radiology Department.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2022.976364/full#supplementary-material

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2018) 68:394–424. doi: 10.3322/caac.21492
2. Cheon SH, Rha SY, Jeung HC, Im CK, Kim SH, Kim HR, et al. Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol. (2008) 19:1146–53. doi: 10.1093/annonc/mdn026
3. Zhang K, Chen L. Chinese consensus on the diagnosis and treatment of gastric cancer with liver metastases. Ther Adv Med Oncol. (2020) 12.1758835920904803. doi: 10.17777/1758835920904803
4. Muro K, Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J, et al. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol. (2019) 30:19–33. doi: 10.1093/annonc/mdy502
5. Takemura N, Saiura A, Koga R, Arita J, Yoshioka R, Ono Y, et al. Long-term outcomes after surgical resection for gastric cancer liver metastasis: an analysis of 64 macroscopically complete resections. Langenbecks Arch Surg. (2012) 397:951–7. doi: 10.1007/s00423-012-0959-z
6. Okano K, Maeba T, Ishimura K, Karasawa Y, Goda F, Wakabayashi H, et al. Hepatic resection for metastatic tumors from gastric cancer. Ann Surg. (2002) 235:86–91. doi: 10.1097/00000658-200201000-00011
7. Oki E, Tokunaga S, Emi Y, Kusumoto T, Yamamoto M, Fukuzawa K, et al. Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCCL302). Gastric Cancer. (2016) 19:968–76. doi: 10.1007/s10120-015-0530-z
8. Markar SR, Mackenzie H, Mikhail S, Mughal M, Preston SR, Maynard ND, et al. Surgical resection of hepatic metastases from gastric cancer: outcomes from national series in England. Gastric Cancer. (2017) 20:379–86. doi: 10.1007/s10120-016-0604-6
9. Kinoshita T, Kinoshita T, Saiura A, Esaki M, Sakamoto H, Yamanaka T, et al. Multicentre analysis of long-term outcome after surgical resection for gastric cancer liver metastases. Br J Surg. (2015) 102:102–7. doi: 10.1002/bjs.9684
10. Okugawa Y, Toiyama Y, Yamamoto A, Shigemori T, Ichikawa T, Yin C, et al. Lymphocyte-to-C-reactive protein ratio and score are clinically feasible nutrition-inflammation markers of outcome in patients with gastric cancer. Clin Nutr. (2020) 39:1209–17. doi: 10.1016/j.clnu.2019.05.009
11. Cheng CB, Zhang QX, Zhaung LP, Sun J.W. Prognostic value of lymphocyte-to-C-reactive protein ratio in patients with gastric cancer after surgery: a multicentre study. Jpn J Clin Oncol. (2020) 50:1141–9. doi: 10.1093/jjco/hyaa099
12. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. (2019) 48:16–31. doi: 10.1093/ageing/afy169
13. Yang Z, Zhou X, Ma B, Xing Y, Jiang X, Wang Z, et al. Predictive value of preoperative sarcopenia in patients with gastric cancer: a meta-analysis and systematic review. *J Gastrointest Surg.* (2018) 22:1890-902. doi: 10.1007/s11605-018-3856-0

14. Kamarajah SK, Bundred J, Tan BHL. Body composition assessment and sarcopenia in patients with gastric cancer: a systematic review and meta-analysis. *Gastric Cancer.* (2019) 22:10-22. doi: 10.1007/s10120-018-0882-2

15. Xiong J, Wu Y, Hu H, Kang W, Li Y, Jin P, et al. Prognostic significance of preoperative sarcopenia in patients with gastric cancer liver metastases receiving hepatectomy. *Front Nutr.* (2022) 9:878791. doi: 10.3389/fnut.2022.878791

16. Xiong J, Hu H, Kang W, Li Y, Jin P, Shao X, et al. Peking prognostic score, based on preoperative sarcopenia status, is a novel prognostic factor in patients with gastric cancer. *Front Nutr.* (2022) 9:910271. doi: 10.3389/fnut.2022.910271

17. Strasberg SM, Phillips C. Use and dissemination of the brisbane 2000 nomenclature of liver anatomy and resections. *Ann Surg.* (2013) 257:377-82. doi: 10.1097/SLA.0b013e31825a01f6

18. Zhuang CL, Huang DD, Pang WY, Zhou CJ, Wang SL, Lou N, et al. Sarcopenia is an independent predictor of severe postoperative complications and long-term survival after radical gastrectomy for gastric cancer: analysis from a large-scale cohort. *Medicine (Baltimore).* (2016) 95:e3164. doi: 10.1097/md.0000000000003164

19. Wagner AD, Unverzagt S, Grothe W, Yong WP, Tai BC, et al. Chemotherapy for advanced gastric cancer. *Cochrane Database Syst Rev.* (2010) 3:CD004064. doi: 10.1002/14651858.CD004064.pub3

20. Markar SR, Mikhail S, Malietzis G, Athanasiou T, Mariette C, Sasako M, et al. Influence of surgical resection of hepatic metastases from gastric adenocarcinoma on long-term survival: systematic review and pooled analysis. *Ann Surg.* (2016) 263:1092-101. doi: 10.1097/SLA.00000000000011742

21. Montagnani F, Crivelli F, Aprili G, Vivaldi C, Pecora I, De Vivo R, et al. Long-term survival after liver metastasectomy in gastric cancer: systematic review and meta-analysis of prognostic factors. *Cancer Treat Rev.* (2018) 69:11-20. doi: 10.1016/j.ctrvr.2018.05.010

22. Okgawara Y, Toiyama Y, Yamamoto A, Shigemori T, Ide S, Kitajima T, et al. Lymphocyte-C-reactive protein ratio as promising new marker for predicting surgical and oncological outcomes in colorectal cancer. *Ann Surg.* (2020) 272:342-51. doi: 10.1097/lsa.0000000000003239

23. Nakamura Y, Shida D, Boku N, Yoshida T, Tanabe T, Takamizawa Y, et al. Lymphocyte-to-C-reactive protein ratio is the most sensitive inflammation-based prognostic score in patients with unresectable metastatic colorectal cancer. *Dis Colon Rectum.* (2021) 64:1331-41. doi: 10.1097/dcr.0000000000002059

24. Yu H, Wang M, Wang Y, Yang J, Deng L, Bao W, et al. The prognostic value of sarcopenia combined with preoperative fibrinogen-albumin ratio in patients with intrahepatic cholangiocarcinoma after surgery: a multicenter, prospective study. *Cancer Med.* (2021) 10:4768-80. doi: 10.1002/cam4.4035

25. Deng JP, Hua X, Long QZ, Zhang WW, Lin HX, He ZY, et al. Prognostic value of skeletal muscle index and monocyte-to-lymphocyte ratio for lymph node-positive breast cancer patients after mastectomy. *Ann Transl Med.* (2019) 7:775. doi: 10.21037/atm.2019.11.37

26. Higgins MI, Martini DJ, Patel DH, Nabavizadeh R, Steele S, Williams M, et al. Sarcopenia and modified glasgow prognostic score predict postsurgical outcomes in localized renal cell carcinoma. *Cancer.* (2021) 127:1974-83. doi: 10.1002/cncr.33462

27. Shigeto K, Kawaguchi T, Koya S, Hirota K, Tanaka T, Nagasu S, et al. Profiles combining muscle atrophy and neutrophil-to-lymphocyte ratio are associated with prognosis of patients with stage IV gastric cancer. *Nutrients.* (2020) 12:884. doi: 10.3390/nu12061884

28. Lee BM, Cho Y, Kim JW, Jeung HC, Lee JI. Prognostic significance of sarcopenia in advanced biliary tract cancer patients. *Front Oncol.* (2020) 10:1581. doi: 10.3389/fonc.2020.01581

29. Feliciano EMC, Kroenke CH, Meyerhardt JA, Prado CM, Bradshaw PT, Kwan ML, et al. Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer: results from the C SCANS study. *JAMA Oncol.* (2017) 3:e172319. doi: 10.1001/jamaoncol.2017.2319

30. Ignacio de Ulíbarri J, González-Madroño A, de Villar NG, González P, González B, Mancha A, et al. CONUT: a tool for controlling nutritional status. First validation in a hospital population. *Nutr Hosp.* (2005) 20:38-45.

31. Kuroda D, Sawayama H, Kurashige J, Iwatsuki M, Eto T, Tokunaga R, et al. Controlling nutritional status (CONUT) score is a prognostic marker for gastric cancer patients after curative resection. *Gastric Cancer.* (2018) 21:204-12. doi: 10.1007/s10120-017-0744-3